Newsmeme!
Discover News you didn't know existed
Stromal Cells
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Cut in import duty on life saving drugs to help only MNCs: Kiran Mazumdar-Shaw
Published July 9, 2009, 7:48 pm, PharmaBiz
The reduction in customs duty of life saving drugs in the Union Budget 2009-10 has not enthused the members of the Indian biotech industry. They are of the view that the move can mainly help the multinational drug companies.
Griffin Securities Initiates Independent Research Coverage on Pluristem Therapeutics Inc.
Published July 8, 2009, 5:00 am, Business Wire via Yahoo! Finance
HAIFA, Israel----Pluristem Therapeutics Inc. , a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient cell therapy products for a variety of disorders, announced today that Griffin Securities has initiated independent research coverage of Pluristem's stock.
Mouse Model Improves Understanding Of Tumor Growth
Published July 8, 2009, 3:13 am, Medical News Today
Cancerous tumors sometimes form at the site of chronic wounds or injury, but the reason why is not entirely clear. Now researchers at Washington University School of Medicine in St. Louis have engineered mice with a persistent wound-like skin condition, and the mice are helping them understand the tumor-promoting effects of long-standing wounds and injuries.
Cytheris Announces Notice of Allowance for U.S. Patent Covering the Pharmaceutical Composition of Its Recombinant ...
Published July 8, 2009, 3:00 am, Business Wire via Yahoo! Finance
PARIS----Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S.
Pluristem Therapeutics Announces First Patient Enrollment In Phase I Clinical Trial For Treatment Of Peripheral Artery ...
Published July 7, 2009, 9:15 am, Medical News Today
Pluristem Therapeutics Inc. (NasdaqCM:PSTI) (DAX:PJT), a bio-therapeutics company dedicated to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for a variety of disorders, announced today that the first patient has been enrolled in a Phase I clinical trial of the Company's allogeneic placental-derived adherent stromal cell product, termed PLX-PAD.
Mice with skin condition help scientists understand tumor growth
Published July 6, 2009, 9:20 am, EurekAlert!
( Washington University School of Medicine ) Cancerous tumors sometimes form at the site of chronic wounds or injury, but the reason why is not entirely clear. Now researchers at Washington University School of Medicine in St. Louis have engineered mice with a persistent wound-like skin condition, and the mice are helping them understand the tumor-promoting effects of long-standing wounds and ...
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |